Ocugen, Inc. to Present at H.C. Wainwright Global Investment Conference
May 23 2022 - 7:34AM
Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on
discovering, developing, and commercializing novel gene therapies,
biologicals and vaccines, today announced that Dr. Shankar
Musunuri, Chairman, CEO and Co-Founder of Ocugen, will participate
in an in-person fireside chat at the H.C. Wainwright Global
Investment Conference, on May 24, 2022, at 1:30pm ET in Miami
Beach, Florida.
Registration is available for those who want to watch the
presentation virtually. A replay of the fireside chat will be
available through the Investor’s section of the Ocugen website
starting on May 24 and for approximately 90 days
following the conference.
About Ocugen, Inc.Ocugen, Inc. is a
biotechnology company focused on discovering, developing, and
commercializing novel gene therapies, biologicals and vaccines that
improve health and offer hope for people and global communities. We
are making an impact through courageous innovation, taking science
in new directions in service of patients. Our breakthrough modifier
gene therapy platform has the potential to treat multiple diseases
with one drug and we are advancing research in other therapeutic
areas to offer new options for people with unmet medical needs.
Discover more at www.ocugen.com and follow us
on Twitter and LinkedIn.
Cautionary Note on Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995, which are subject to risks and uncertainties.
We may, in some cases, use terms such as “predicts,” “believes,”
“potential,” “proposed,” “continue,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should” or other words that convey uncertainty of future events or
outcomes to identify these forward-looking statements. Such
statements are subject to numerous important factors, risks and
uncertainties that may cause actual events or results to differ
materially from our current expectations. These and other risks and
uncertainties are more fully described in our periodic filings with
the Securities and Exchange Commission (“SEC”), including the risk
factors described in the section entitled “Risk Factors” in the
quarterly and annual reports that we file with the SEC. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. Except as required by
law, we assume no obligation to update forward-looking statements
contained in this press release whether as a result of new
information, future events or otherwise, after the date of this
press release.
Ocugen Contact: Ken InchaustiHead,
Investor Relations & Communicationsken.inchausti@ocugen.com
For investor-related inquiries: IR@Ocugen.com
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Apr 2023 to Apr 2024